JP2018512435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512435A5 JP2018512435A5 JP2017553974A JP2017553974A JP2018512435A5 JP 2018512435 A5 JP2018512435 A5 JP 2018512435A5 JP 2017553974 A JP2017553974 A JP 2017553974A JP 2017553974 A JP2017553974 A JP 2017553974A JP 2018512435 A5 JP2018512435 A5 JP 2018512435A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- amino acid
- antibody
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147853P | 2015-04-15 | 2015-04-15 | |
| US62/147,853 | 2015-04-15 | ||
| US201562234899P | 2015-09-30 | 2015-09-30 | |
| US62/234,899 | 2015-09-30 | ||
| US201562261528P | 2015-12-01 | 2015-12-01 | |
| US62/261,528 | 2015-12-01 | ||
| PCT/US2016/027774 WO2016168613A1 (en) | 2015-04-15 | 2016-04-15 | Methods of increasing strength and functionality with gdf8 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512435A JP2018512435A (ja) | 2018-05-17 |
| JP2018512435A5 true JP2018512435A5 (OSRAM) | 2019-05-09 |
| JP6877357B2 JP6877357B2 (ja) | 2021-05-26 |
Family
ID=55809250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553974A Active JP6877357B2 (ja) | 2015-04-15 | 2016-04-15 | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10934349B2 (OSRAM) |
| EP (1) | EP3283519A1 (OSRAM) |
| JP (1) | JP6877357B2 (OSRAM) |
| KR (2) | KR20170135967A (OSRAM) |
| CN (1) | CN107771081A (OSRAM) |
| AU (1) | AU2016249015B2 (OSRAM) |
| CA (1) | CA2982810A1 (OSRAM) |
| EA (1) | EA201792298A1 (OSRAM) |
| HK (1) | HK1250236A1 (OSRAM) |
| IL (1) | IL255010B2 (OSRAM) |
| MA (1) | MA49661A (OSRAM) |
| MX (1) | MX2017013267A (OSRAM) |
| WO (1) | WO2016168613A1 (OSRAM) |
| ZA (1) | ZA201707550B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| RS62330B1 (sr) | 2015-09-15 | 2021-10-29 | Scholar Rock Inc | Antitela pro/latentnog miostatina i njihova upotreba |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| US10287345B2 (en) | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
| KR20210082548A (ko) * | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| SI3565592T1 (sl) | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
| US11248044B2 (en) * | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
| JP7420730B2 (ja) | 2018-04-06 | 2024-01-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 |
| KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
| CN111303280B (zh) * | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
| WO2022092294A1 (ja) | 2020-10-30 | 2022-05-05 | 学校法人慶應義塾 | サルコペニア関連疾患等の新規治療および予防 |
| US20250161255A1 (en) | 2022-01-25 | 2025-05-22 | Motoshi Hayano | New therapy and prevention for suppressing aging-related disorders including sarcopenia |
| KR20250122524A (ko) | 2022-12-22 | 2025-08-13 | 스칼러 락, 인크. | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1910220A (en) * | 1931-10-21 | 1933-05-23 | Kremser Alois | Mechanically operated gate |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| EE200200025A (et) | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
| US6670140B2 (en) | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7785587B2 (en) | 2003-06-02 | 2010-08-31 | Wyeth | Therapeutic methods for muscular or neuromuscular disorders |
| WO2005066204A2 (en) | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| AU2005227896B2 (en) | 2004-03-23 | 2008-11-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EA201100642A1 (ru) | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| EP1773041A1 (en) | 2005-07-21 | 2007-04-11 | Chao-Hung Wu | Audio/video data transmission system using the internet to interconnect telephones |
| PT2407486T (pt) | 2005-08-19 | 2018-02-21 | Univ Pennsylvania | Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8 |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| US8309068B2 (en) | 2006-08-03 | 2012-11-13 | Myostin Therapeutics Pty Ltd. | Isolated polypeptides and methods of improving muscle strength |
| UA98308C2 (en) | 2006-09-05 | 2012-05-10 | Эли Лилли Энд Компани | Anti-myostatin antibody |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| DK2207775T3 (da) | 2007-11-05 | 2012-06-18 | Novartis Ag | 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| NO2424895T3 (OSRAM) | 2009-04-27 | 2018-02-03 | ||
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| CA2835819A1 (en) | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| WO2013186719A1 (en) * | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
| CA2899889A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| TW201536318A (zh) * | 2013-08-14 | 2015-10-01 | Novartis Ag | 治療偶發性包涵體肌炎之方法 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| US11248044B2 (en) | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
-
2016
- 2016-04-15 KR KR1020177032792A patent/KR20170135967A/ko not_active Ceased
- 2016-04-15 CA CA2982810A patent/CA2982810A1/en active Pending
- 2016-04-15 AU AU2016249015A patent/AU2016249015B2/en active Active
- 2016-04-15 CN CN201680035382.9A patent/CN107771081A/zh active Pending
- 2016-04-15 US US15/099,701 patent/US10934349B2/en active Active
- 2016-04-15 MA MA049661A patent/MA49661A/fr unknown
- 2016-04-15 EP EP16718831.7A patent/EP3283519A1/en active Pending
- 2016-04-15 IL IL255010A patent/IL255010B2/en unknown
- 2016-04-15 EA EA201792298A patent/EA201792298A1/ru unknown
- 2016-04-15 WO PCT/US2016/027774 patent/WO2016168613A1/en not_active Ceased
- 2016-04-15 HK HK18109657.5A patent/HK1250236A1/zh unknown
- 2016-04-15 KR KR1020247027318A patent/KR20240128136A/ko active Pending
- 2016-04-15 MX MX2017013267A patent/MX2017013267A/es unknown
- 2016-04-15 JP JP2017553974A patent/JP6877357B2/ja active Active
-
2017
- 2017-11-08 ZA ZA2017/07550A patent/ZA201707550B/en unknown
-
2021
- 2021-01-14 US US17/149,540 patent/US12029788B2/en active Active
-
2024
- 2024-05-24 US US18/674,399 patent/US20240390489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512435A5 (OSRAM) | ||
| JP6877357B2 (ja) | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 | |
| JP2016528247A5 (OSRAM) | ||
| JP2011506483A5 (OSRAM) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2014533279A5 (OSRAM) | ||
| JP2017507139A5 (OSRAM) | ||
| JP2015514110A5 (OSRAM) | ||
| JP2016501892A5 (OSRAM) | ||
| JP2016507470A5 (OSRAM) | ||
| JP2018500014A5 (OSRAM) | ||
| JP2018503361A5 (OSRAM) | ||
| JP2019523295A5 (OSRAM) | ||
| JP2015517529A5 (OSRAM) | ||
| JP2006522830A5 (OSRAM) | ||
| JP2013542194A5 (OSRAM) | ||
| JP2014534956A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| IL273678B2 (en) | Methods for treating allergy and improving allergen-specific immunotherapy by administering an IL-4R inhibitor | |
| IL272674B2 (en) | Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2015505564A5 (OSRAM) | ||
| JP2019528285A5 (OSRAM) | ||
| JP2018529661A5 (OSRAM) | ||
| IL276921B1 (en) | Methods for altering body composition |